Management Tasks

Focusing on Takeda-ism, which represents the corporate philosophy referring to "Integrity = fairness, honesty, perseverance " as the basis of all the business activities, Takeda is aiming to realize sustainable growth and increased corporate value globally by achieving the targets set in this Medium-Term Management Plan, with comprehensive improvement of strengths such as "establishment and in-depth implementation of strategies from a long-term perspective" and "high productivity and efficiency."

In "2006-2010 Medium-Term Management Plan," Takeda will dedicate collective efforts to the management tasks mentioned below (blue title). In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, Takeda has created corporate-level, center of excellence research & development, commercial and administrative functions.

March 31, 2009   Takeda to Create Global Centers of Excellence

Enhancement of capability to create new drugs through in-house R&D activities

March 31, 2009   Takeda to Create Global Centers of Excellence
Takeda has created corporate-level, center of excellence R&D. Chief Scientific Officer (CSO) is responsible for global Research, Development, Chemistry Manufacturing and Controls, and Intellectual Property. The creation of the CSO role provides the opportunity to further enhance product development effectiveness through the integration of research and development.

September 25, 2008 Takeda Established a New Company for Clinical Development in the Asia-Oceania Region
Takeda has established a wholly-owned subsidiary, "Takeda Clinical Research Singapore Private Limited" in the Republic of Singapore to serve as its center of clinical development in the Asia-Oceania region.

April 10, 2008 Takeda to Acquire Millennium
Takeda and Millennium Pharmaceuticals, Inc.have entered into a definitive agreement pursuant to which Takeda will acquire Millennium through a cash tender offer. Millennium is a leading biopharmaceutical company. The acquisition of Millennium accelerates Takeda’s vision of becoming a global leader in oncology with critical mass in the areas of oncology discovery, development, regulatory affairs and commercialization.

April 01, 2008 Launch of Takeda Bio Development Center Limited
Takeda Bio Development Center Limited, which used to be a wholly owned subsidiary of Amgen Inc. in Japan being engaged in the clinical development of the investigational compounds created by Amgen Inc., has become a wholly owned subsidiary of Takeda.

November 19, 2007 Takeda Established a New Company in the U.S. for Therapeutic Antibody Research
Takeda has established a new company for therapeutic antibody research, Takeda San Francisco, Inc.
Located in San Francisco as one of the bio-pharma clusters, TSF will be positioned as a center of excellence for Takeda’s therapeutic antibody research.

Formulation of a tri-polar marketing function (Japan, USA, Europe)

December 02, 2009   Takeda to Continue Strategic Expansion with Operations in Brazil
Takeda will establish a new commercial subsidiary in Brazil, the largest country in Latin America with a population of approximately 196 million people. The Brazilian pharmaceutical market accounts for more than 40 percent of the pharmaceutical sales throughout Latin America and is forecasted to grow by 8.5 percent every year until the year 2013.

October 01, 2009   Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
Takeda established Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) – as part of Takeda's strategic global expansion efforts.

May 07, 2009   Takeda to Start Sales and Marketing Operation in Portugal
Takeda established Takeda Farmacêuticos Portugal, Unipessoal, Lda and started its own wholly owned sales and marketing operation in Portugal.

March 31, 2009   Takeda to Create Global Centers of Excellence
Takeda has created corporate-level, center of international commercial function. Executive Vice President (EVP), International Operations is responsible for all international (ex-Japan) commercial operations in the United States, Europe, and Asia, as well as global medical affairs and international marketing. The creation of the EVP, International Operations role enhances Takeda’s globalization efforts and allows for more streamlined commercial decision making.

March 30, 2009  Takeda Expands its Own Sales and Marketing Operations in Europe
Takeda Farmacéutica España S.A. established in Spain, the European fifth largest pharmaceutical market.
Takeda also expands its operations in the Republic of Ireland to cover the entire country, which used to be limited in a specific area.

March 27, 2009  Takeda Establishes Presence in Canada
Takeda Canada Inc., established in Mississauga, Ontario, one of the top three biotech areas in North America. Takeda expands into the world’s eighth largest pharmaceutical market.

September 25, 2008 Takeda Established a New Company for Asian Sales & Marketing
Takeda has established a wholly-owned subsidiary for overall Asian sales and marketing, Takeda Pharmaceuticals Asia Private Limited in the Republic of Singapore.

Securing the human resources pipeline necessary for global operation.

April 13, 2007 TAKEDA to Start the Global Leadership Training Program
Takeda started its group-wide global leadership training program called "Takeda Leadership Institute" ("TLI") with the support of INSEAD, which is one of the world's leading graduate business schools.